07:38 EST Ocular Therapeutix (OCUL) up 13% at $14.22 on accelerated AXPAXLI NDA submission plans
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular announces plans to accelerate AXPAXLI NDA submission timeline
- Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
- Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
- Ocular Therapeutix Prepares NDA Submission for Wet AMD Drug
- Ocular Therapeutix reports inducement grant under Nasdaq listing rule